The FDA announced on 2026-04-02 a significant update to the indication and usage section of the Dapagliflozin label. This revision specifies that Dapagliflozin is now indicated to reduce the risk of hospitalization for heart failure. This new indication applies to adults diagnosed with type 2 diabetes mellitus who also present with either established cardiovascular disease or multiple cardiovascular risk factors.
Background
Dapagliflozin, also known by its brand name Farxiga, is a medication that has received an expanded indication from the FDA. The updated label clarifies its role in cardiovascular risk management for a specific patient population. This latest update, effective 2026-04-02, focuses on its benefit in reducing a critical cardiovascular outcome: hospitalization for heart failure. The target population for this specific indication includes adults who have type 2 diabetes mellitus and are further characterized by the presence of established cardiovascular disease or multiple cardiovascular risk factors. This expansion builds upon the drug's existing profile in managing type 2 diabetes.
What this means
This FDA label revision for Dapagliflozin offers clinicians a new tool in managing the complex interplay between type 2 diabetes and cardiovascular health. The explicit indication to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus, particularly those with existing cardiovascular disease or multiple risk factors, provides clear guidance for its use. Heart failure is a common and serious complication in patients with type 2 diabetes, often leading to frequent hospitalizations and reduced quality of life. By specifically targeting this risk, Dapagliflozin can play a crucial role in preventative strategies. This update encourages healthcare providers to consider Dapagliflozin for its cardioprotective effects in this high-risk group, potentially leading to improved patient outcomes and a reduction in the burden of heart failure-related hospitalizations.
Source
The information regarding this label revision for Dapagliflozin was sourced from the FDA. The update became effective on 2026-04-02, and details are available on the DailyMed platform, hosted by the National Library of Medicine (dailymed.nlm.nih.gov).